Johnson & Johnson annual operating margin
2009
2010
2011
2012
2013
2014
2022
2023
2024
2025
Johnson & Johnson Operating Margin Growth & History (JNJ)
Johnson & Johnson's operating margin was 27.17% for fiscal 2025.
View full Johnson & Johnson company overviewJohnson & Johnson annual operating margin history
| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-28 | 27.17% | +3.25 pp |
| 2024 | 2024-12-29 | 23.92% | −1.92 pp |
| 2023 | 2023-12-31 | 25.84% | −0.42 pp |
| 2022 | 2023-01-01 | 26.27% | — |
| 2014 | 2014-12-28 | 29.05% | +6.03 pp |
| 2013 | 2013-12-29 | 23.01% | +0.77 pp |
| 2012 | 2012-12-30 | 22.25% | +1.08 pp |
| 2011 | 2012-01-01 | 21.17% | −7.57 pp |
| 2010 | 2011-01-02 | 28.74% | +1.95 pp |
| 2009 | 2010-01-03 | 26.79% | — |
Johnson & Johnson quarterly operating margin
Q2.10
Q3.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-28 | 28.34% | +0.08 pp |
| Q1 2026 | 2026-03-29 | 26.58% | — |
| Q4 2025 | 2025-12-28 | 22.76% | — |
| Q3 2025 | 2025-09-28 | 29.58% | — |
| Q2 2025 | 2025-06-29 | 28.26% | — |
| Q1 2015 | 2015-03-29 | 33.54% | +2.34 pp |
| Q4 2014 | 2014-12-28 | 16.50% | −0.06 pp |
| Q3 2014 | 2014-09-28 | 38.19% | +16.16 pp |
| Q2 2014 | 2014-06-29 | 30.14% | +2.06 pp |
| Q1 2014 | 2014-03-30 | 31.20% | +5.59 pp |
| Q4 2013 | 2013-12-29 | 16.55% | −2.49 pp |
| Q3 2013 | 2013-09-29 | 22.03% | −0.40 pp |
| Q2 2013 | 2013-06-30 | 28.08% | +11.95 pp |
| Q1 2013 | 2013-03-31 | 25.60% | −6.18 pp |
| Q4 2012 | 2012-12-30 | 19.04% | +13.80 pp |
| Q3 2012 | 2012-09-30 | 22.43% | −6.62 pp |
| Q2 2012 | 2012-07-01 | 16.13% | −5.19 pp |
| Q1 2012 | 2012-04-01 | 31.79% | +2.56 pp |
| Q4 2011 | 2012-01-01 | 5.24% | — |
| Q3 2011 | 2011-10-02 | 29.05% | −0.06 pp |
| Q2 2011 | 2011-07-03 | 21.32% | −7.24 pp |
| Q1 2011 | 2011-04-03 | 29.22% | — |
| Q3 2010 | 2010-10-03 | 29.11% | — |
| Q2 2010 | 2010-07-04 | 28.56% | — |
Johnson & Johnson operating margin trends
Between the periods ended 2010-01-03 and 2025-12-28, Johnson & Johnson's operating margin increased from 26.79% to 27.17%, a change of +0.38 percentage points. The latest reported quarter, Q2 2026, shows 28.34%.
About the metric
What operating margin means
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
Calculation and source
How operating margin is calculated
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Johnson & Johnson source filings ↗Community posts
J&J reports surgery-comparator benefit for Erleada in prostate cancer
Johnson & Johnson ($JNJ) reported new PROTEUS substudy results comparing Erleada plus hormone therapy before and after prostate surgery with surgery alone. Among 408 patients with high-risk localized or locally advanced disease, the regimen ...
J&J reports early prostate-cancer responses for experimental oral drug
Johnson & Johnson ($JNJ) disclosed early results for oral JNJ-6143 in heavily pretreated advanced prostate cancer. Among 31 evaluable patients receiving 50 milligrams, 77% achieved at least a 50% PSA decline. Confirmed tumor responses occur ...
Carvykti follow-up finds half of a small cohort progression-free at five years
Johnson & Johnson ($JNJ) and Legend Biotech ($LEGN) reported five-year follow-up from 20 patients in the Phase 2 CARTITUDE-2 Cohort A study of Carvykti. Ten remained alive without disease progression or further anti-myeloma treatment after ...
Johnson & Johnson says Tremfya meets axial psoriatic-arthritis trial goals
Johnson & Johnson ($JNJ) said Tremfya met the primary and key secondary endpoints in STAR, a randomized, double-blind Phase 4 study in patients with axial manifestations of psoriatic arthritis. The company reported improvement over placebo ...
Apollo reportedly nears $20 billion talks for J&J orthopedics business
Apollo ($APO) is in talks to acquire Johnson & Johnson’s ($JNJ) DePuy Synthes orthopedics business in a transaction that could be worth around $20 billion, Reuters reported, citing Bloomberg. The unit generated approximately $9.3 billion in ...
